An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Astria Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Astria Therapeutics (NASDAQ: ATXS) has successfully closed its underwritten offering of 10,445,050 shares at $11.01 per share, raising approximately $115 million in gross proceeds. The offering included the full exercise of an underwriters' option for 1,362,397 additional shares. Jefferies and Evercore ISI served as joint book-running managers. The shares were offered under an effective shelf registration statement filed with the SEC. This funding supports the company's development of STAR-0215, aimed at treating hereditary angioedema and other rare diseases.
Positive
Raised approximately $115 million in gross proceeds from the offering.
Successful closure of offering indicates strong investor interest.
Supports the development of STAR-0215 for hereditary angioedema.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Astria Therapeutics, Inc. (“Astria Therapeutics,” “Astria,” the “Company,” “our,” or “us”) (Nasdaq: ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced the closing of its previously announced underwritten offering of 10,445,050 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,362,397 shares of common stock, at a price of $11.01 per share. The gross proceeds of the offering were approximately $115 million, before deducting underwriting discounts and commissions and other offering expenses. All shares in the offering were offered by the Company.
Jefferies and Evercore ISI acted as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. acted as co-lead managers and H.C. Wainwright & Co. acted as co-manager for the offering.
The shares described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-264911), which was declared effective by the Securities and Exchange Commission (the “SEC”) on May 23, 2022. The offering was made only by means of a prospectus supplement and the accompanying prospectus. A prospectus supplement relating to the offering has been filed with the SEC and is available at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus may be obtained for free by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the shares described herein, nor shall there be any sale of these shares in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
About Astria Therapeutics
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema.
